MRTFA and systemic sclerosis: It is possible that drug therapies which target MRTF-A signaling could uncouple the persistent fibrosis from mechanical stress in SSc tissues leading to resolution or improvement, or would improve the responses to immunosuppressive or targeted anti-inflammatory treatments.